ArticleFrontiers in microbiology2025
Development of a smartphone camera-based chemiluminescent lateral flow immunoassay for detecting African swine fever virus antibodies.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Colorimetric/chemiluminescent vertical flow immunoassay based on multifunctional cobalt-gold bimetallic nanoclusters for Brucella antibody detection and deep learning-assisted semiquantitative analysis.Mikrochimica acta · 2026Article
- Innovations, Applications, and Future Trends in Veterinary Diagnostic Technologies.Transboundary and emerging diseases · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
African swine fever (ASF) is a highly contagious viral disease threatening global swine industries. Rapid and accurate detection of ASF virus (ASFV) antibodies is crucial for disease surveillance and control. The gold lateral flow immunoassay (GLFIA) is cost-effective and has been successfully applied in rapid on-site detection of ASFV. However, its sensitivity is relatively low. To enhance the detection sensitivity and accuracy while retaining convenience, we developed a chemiluminescent lateral flow immunoassay (CLFIA) for detecting ASFV antibodies based on the p72 trimer protein, which can immediately read the chemiluminescent signal through the camera of a smartphone. Compared with GLFIA and commercial enzyme-linked immunosorbent assay (ELISA), its sensitivity was improved by at least two orders of magnitude and nine orders of magnitude, respectively. Additionally, CLFIA shows no cross-reaction with antibodies from common swine disease viruses, and the detection results of 65 clinical samples have a 93.8% coincidence rate with those of commercial ELISA kits. This research successfully addressed the issue that traditional chemiluminescent detection relies on specialized instruments, providing a new technical approach for the highly sensitive and rapid detection of ASFV, and effectively promoting the development and application of CLFIA technology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.